Stem cells are preliminary body cells from which all other cells with specialized functions are generated. Under a controlled environment in the body or a clinical laboratory, these cells divide to form more cells called daughter cells. Due to the advent of modern health science, these cells play a major role in understanding the occurrence of diseases, the generation of advanced regenerative medicines, and drug discovery. There are certain sources such as embryos, bone marrow, body fats, and umbilical cord blood amongst others, where stem cells are generated.
MEDIPOST and U.S. Stem Cell, Inc – are Notable Market Players in the Global Stem Cell Therapy Market
Leading companies operating in the global stem cell therapy market have undertaken various organic and inorganic growth strategies. The global stem cell therapy market comprises MEDIPOST, Pharmicell Co., Inc; RichSource, BioTime, Inc.; Mesoblast Limited, Holostem Terapie Avanzate Srl; U.S. Stem Cell, Inc; Caladrius Biosciences, Inc.; TiGenix NV, AlloSource. The companies have been implementing various strategies that have helped their growth and, in turn, brought about several breakthroughs and transitions in the industry. The companies have utilized organic strategies such as product launches in the global stem cell therapy market, resulting in the market’s growth. Moreover, the market players have also deployed several inorganic strategies, including mergers & acquisitions and collaborations that helped the Company to strengthen its revenue, which allows the Company to hold a strong position in the market.
Below are the major growth strategies undertaken by the players operating in the global stem cell therapy market:
|
YEAR |
NEWS |
|
Oct-2022 |
Medipost (CEO Won-Il Oh) announced its new GMP facilities will house ten cleanrooms and production facilities equipped with up-to-date equipment exclusively for Contract Development and Manufacturing Organization (CDMO), marking the launch of its CDMO business for cell and gene therapy products in Korea. |
|
Sep-2022 |
Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. announced that the proposed merger of the two companies has closed following the approval of Caladrius’ stockholders on September 13, 2022. The merged company will operate as Lisata Therapeutics, Inc. and will focus primarily on advancing its CendR Platform technology product candidates in a range of oncology indications, in addition to Caladrius’ existing development programs. |
|
June-2021 |
Allogene Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALLO-605, the Company’s next-generation AlloCAR T therapy targeting BCMA for the treatment of relapsed or refractory multiple myeloma. The FDA granted Fast Track designation based on the potential of ALLO-605 to address the unmet need for patients who have failed other standard multiple myeloma therapies. |
|
May-2021 |
Spacelabs Healthcare a division of OSI Systems, Inc. launched Lifescreen Pro event screening system to diagnose cardiac arrhythmias accurately and economically. Lifescreen Pro expands the Company’s non-invasive cardiology offerings. |
